What are SS-31 and MOTS-c, and what does an SS-31 dosage search ask?
On this site, SS-31 refers to elamipretide (development codes MTP-131 and Bendavia in the FDA review [2]), a tetrapeptide that binds cardiolipin in the inner mitochondrial membrane. The FDA label describes it as a mitochondrial cardiolipin binder and approves it, under the brand name Forzinity, to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg, under accelerated approval [1]. MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA, studied in cells and mice [4].
Searches such as ss-31 peptide dosage or ss31 peptide dosage want a number. For elamipretide there is a labeled one, but it belongs to one product, one indication and one population. For MOTS-c there is none. A stack search adds a third request, how the two fit together, which no cited source has studied.
What do the elamipretide label and the MOTS-c study report?
The elamipretide label lists 40 mg by subcutaneous injection once daily for patients with Barth syndrome weighing 30 kg or more, with reduced amounts in adults with severe kidney impairment [1]. It supplies the drug as 280 mg in 3.5 mL, or 80 mg/mL, in single-patient-use vials, and it carries warnings about benzyl alcohol in neonates and about hypersensitivity reactions, and lists injection-site reactions. Elamipretide and its two inactive metabolites leave the body in urine, with about 100% of the dose recovered within 48 hours in patients with normal renal function [1]. The label gives maximum concentrations 0.5 to 1 hour after subcutaneous administration and a bioavailability of approximately 92% [1].
The FDA review behind the approval also reports a 40 mg subcutaneous study in 32 healthy volunteers [2]. It reports a mean elamipretide half-life of 3.16 hours after one 40 mg dose in 32 healthy volunteers and 1.48 hours in 7 patients with Barth syndrome; the app uses 3.16 hours [2].
MOTS-c's source is the 2015 discovery paper. It was studied in cells and mice for effects on metabolism [4]. The paper reports no human amount and no half-life. MOTS-c is not an FDA-approved drug, and FDA has identified no human exposure data for it [3]. No human dose has been established. The two peptides share a subject area, not an evidence base.
| Compound | Status | Half-life |
|---|---|---|
| SS-31 | Elamipretide has FDA accelerated approval to improve muscle strength in adult and pediatric patients with Barth syndrome who weigh at least 30 kg; continued approval may depend on a confirmatory trial. | 3.16 hours (mean after one 40 mg subcutaneous dose in 32 healthy volunteers; 1.48 hours in 7 patients with Barth syndrome), per the FDA integrated review; the label states no half-life. |
| MOTS-c | MOTS-c is not an FDA-approved drug; FDA lists it among bulk substances for compounding whose nomination was withdrawn and states it has not identified any human exposure data on drug products containing MOTS-c administered via any route. | No published half-life value exists for MOTS-c in this form. |
How are SS-31 and MOTS-c measured and converted?
Elamipretide comes as a ready solution, so no water is added. The label states that each 0.5 mL dose contains 40 mg and that the dose is measured in millilitres with the syringe prescribed or supplied [1].
For a powder vial, the MOTS-c calculator divides the label amount by the water added; no MOTS-c product is described by any cited source. The MOTS-c calculator and MOTS-c units chart cover the powder; the SS-31 guide covers the labeled solution.
How do people log SS-31 and MOTS-c in PinPoint?
PinPoint tracks each vial separately [5]. An elamipretide vial and a MOTS-c vial are each added with their own expiry, and each injection becomes its own entry with compound, dose, site and pain level [5].
Each compound is logged on the schedule the person enters, with separate reminders [5]. The Home curve uses 3.16 hours for elamipretide (healthy-volunteer mean in the FDA review). No cited source gives a half-life for MOTS-c. The curve does not account for individual variation or for how the two might interact [5].
Get PinPoint on the App StoreWhat do people ask about SS-31 and MOTS-c?
- Is SS-31 FDA approved?
- Elamipretide has an FDA label under the brand name Forzinity for improving muscle strength in Barth syndrome in patients weighing at least 30 kg, under accelerated approval. The approval covers Forzinity only; the label says nothing about products sold as SS-31 for research.
- What dose does the Forzinity label list?
- The label lists 40 mg by subcutaneous injection for patients with Barth syndrome weighing 30 kg or more, with adjustments for severe kidney impairment; the label section above gives its schedule and source. That figure belongs to the labeled indication.
- Has the ss-31 and mots-c combination been studied?
- No cited source studied the two together. Elamipretide has a label and volunteer data; MOTS-c has a cell and mouse discovery paper. No human dose has been established for MOTS-c.
Where do these facts come from?
Sources are listed by kind: labels and regulators first, then peer-reviewed papers, then the app description. Arithmetic is worked from the inputs stated beside it and is not a source; an example vial size is an arithmetic input, not a sourced fact.
- Elamipretide injection prescribing information (DailyMed)FDA label, sections 1, 2 and 3: indication, labeled dosage and the 280 mg/3.5 mL vial.Retrieved 2026-10-05 · label
- FDA integrated review of elamipretide, 2025FDA review document for the elamipretide application.Retrieved 2026-10-05 · regulatory-review
- FDA, certain bulk drug substances for use in compounding that may present significant safety risksContent current as of 22 April 2026; read on 19 November 2026. Ipamorelin acetate in category 2 under the 503B interim policy; CJC-1295 serious adverse events noted; MOTS-c listed with its nomination withdrawn, and no human exposure data identified for drug products containing it.Retrieved 2026-11-19 · regulator
- Discovery of the mitochondrial-derived peptide MOTS-c, 2015Cell Metab, 2015. Cell and mouse studies of metabolic homeostasis.Retrieved 2026-10-05 · study
- PinPoint App Store descriptionFeature wording from the approved application description, not pricing.Retrieved 2026-10-05 · app-description
